Report: Current Stock Reports

Change of publication date of the annual report for 2022
March 10, 2023

Conclusion of an agreement concerning the operational execution of Phase II of Phase I/II clinical trial of RVU120 in Patients with Relapsed/Refractory Solid Tumors
March 2, 2023

Receipt from a person discharging managerial responsibilities in the Company of a correction to the Article 19 MAR notification
February 6, 2023

Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
February 3, 2023

Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
February 3, 2023

Achievement of the first milestone under licence agreement with Exelixis Inc.
January 26, 2023

Announcement of the NDS on registration of series J shares with the NDS
January 25, 2023

Publication dates for periodic reports in 2023
January 25, 2023

Notification from TFI Allianz Polska S.A. of a change in its share in the total number of votes in the Company
January 25, 2023

Admission and introduction of the series J shares of the Company to trading on the regulated market of the WSE
January 20, 2023